Commonly used drugs for the treatment of breast cancer patients like paclitaxel and Herceptin often show severe side effects or induce resistance in clinical settings. Thus, we analysed a combination of Plk1 (polo-like kinase 1)-specific small interfering RNAs (siRNAs), a powerful tool to induce 'mitotic catastrophe' in cancer cells, together with these drugs to identify conditions for enhanced drug sensitivity. After transfection, the antineoplastic agents were added and cell proliferation, apoptosis and cell cycle distribution in breast cancer cells (MCF-7, SK-BR-3, MDA-MB-435 and BT-474) and in primary human mammary epithelial cells were determined. Downregulation of cellular Plk1 levels led to an elevated percentage of cells in G 2 /M phase. The percentage of apoptotic nuclei in MCF-7, MDA-MB-435, SK-BR-3 and BT-474 cells was clearly increased after incubation with Plk1-specific siRNAs and paclitaxel. Interestingly, the caspase pathway was activated after treatment with Plk1-specific siRNAs and paclitaxel or Herceptin. Treatment of breast cancer cells with siRNAs targeting Plk1 improved the sensitivity toward paclitaxel and Herceptin in a synergistic manner. In all experiments, very low concentrations across a wide range of clinically relevant concentrations were sufficient to induce an antiproliferative effect. The combination of Plk1-specific siRNAs with modern breast cancer drugs seems to represent rational combinations to be tested in preclinical trials.
Introduction
Increasing knowledge about the genetic control of cellular proliferation provides the basis for specific therapeutic strategies to combat proliferative disorders like cancer. Key regulators for mitosis in mammalian cells are the polo-like kinases (Plks), which are a group of highly conserved serine/threonine kinases (Barr et al., 2004) . Plk1 activity is elevated in all cancer cells analysed to date (Strebhardt and Ullrich, 2006) . The importance of Plk1 for the aggressiveness of a tumor and for predicting outcomes in cancer patients (Strebhardt, 2001 ) results from its contribution to oncogenic transformation (Smith et al., 1997 (Smith et al., , 2000 Ando et al., 2004) . The inhibition of Plk1 with antibodies, antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs) or dominant-negative mutants leads to 'mitotic catastrophe', increased apoptosis and tumor inhibition (Lane and Nigg, 1996; Cogswell et al., 2000; Spankuch-Schmitt et al., 2002a, b; Liu and Erikson, 2003; Ahmad, 2004; Spankuch et al., 2004; Liu et al., 2006) . Still, instead of hitting a single promising target like Plk1, a combination therapy highly tailored for maximum effects against individual tumors is very often the best option for cancer treatment. In addition, many carcinomas show resistance to antineoplastic drugs, which is a major restriction for chemotherapy of advanced cancers. Although antineoplastic agents like paclitaxel, and the monoclonal antibody Herceptin have already exhibited promising results in clinical trials, multiple cases of low susceptibility to these drugs have made treatment decisions by clinicians difficult (Crown and Pegram, 2003; Nahta and Esteva, 2006b ). For these reasons, improvements of therapeutical regimens are urgently needed.
Recent advances in the field of nucleic acid chemistry offer attractive alternatives to silence gene products important for tumor progression and treatment resistance. One fascinating approach is the use of siRNAs targeted to key elements of proliferation-relevant signaltransduction pathways, which can prevent tumor development in animal models. Therapeutical application of siRNAs will largely depend on the development of a delivery vehicle that can transport synthetic siRNA to target cells. Cationic liposomes or conjugation to cholesterol represent some of the few examples that can meet these requirements (Templeton, 2002; Soutschek et al., 2004) and have even been used for the treatment of primates (Zimmermann et al., 2006) .
The aim of the present study was to combine Plk1-specific siRNAs with paclitaxel, and with the monoclonal antibody Herceptin to test conditions for enhanced drug sensitivity in breast cancer cells compared with primary human mammary epithelial cells (HMECs) . Interestingly, the treatment of cancer cells with Plk1-specific siRNAs made cells more susceptible to paclitaxel and Herceptin, respectively, in a synergistic manner. In primary cells, the effects induced by paclitaxel were not intensified by the addition of Plk1-specific siRNAs.
Results
Reduction of Plk1 mRNA and protein expression in breast cancer cells after treatment with Plk1-specific siRNAs Over the past decade, 'RNA interference' has emerged as a natural and highly efficient mechanism for gene silencing. siRNA4, which has previously been shown to silence Plk1 expression in different cancer cell lines (Spankuch-Schmitt et al., 2002a) , was tested for its ability to downregulate Plk1 mRNA levels in different breast cancer cell lines in very low concentrations compared with our earlier studies. Thus, we analysed the dose-dependent reduction of endogenous Plk1 mRNA (after 24 h) and protein (after 48 h) by Plk1-specific siRNAs in MCF-7, MDA-MB-435, SK-BR-3 and BT-474 cells. In MCF-7 cells, 0.56 and 5.6 nM siRNA4 reduced Plk1 mRNA significantly to 76 and 47% (Po0.01, Figure 1a ). In SK-BR-3 cells, all three siRNA4 concentrations reduced Plk1 mRNA statistically significantly (Figure 1b ): 0.056 nM to 67% (Po0.01), 0.56 nM to 39% (Po0.0001) and 5.6 nM to 52% (Po0.01). In MDA-MB-435 cells, 0.056 nM siRNA4 reduced Plk1 mRNA statistically significantly to 32% (Po0.01; Figure 1c ), 0.56 nM to 39% (Po0.05) and 5.6 nM to 16% (Po0.01). In BT-474 cells, 0.056-5.6 nM siRNA4 did not reduce Plk1 mRNA statistically significantly compared with control cells (P>0.05 for all concentrations; Figure 1d ). In all cell lines, transfection with siRNA4S, a scrambled version of siRNA4, did not alter Plk1 mRNA expression significantly.
Next we analysed whether this reduction of Plk1 mRNA was accompanied by a reduction of Plk1 protein in MCF-7 cells (Figure 2a ): 0.056 nM siRNA4 significantly reduced Plk1 protein expression levels to 39% (Po0.001), 0.56 nM to 19% (Po0.0001) and 5.6 nM to 21% (Po0.01). In SK-BR-3 cells, 0.056 nM siRNA4 reduced Plk1 protein significantly to 49% (Po0.0001; Figure 2b ), 0.56 nM to 27% (Po0.001) and 5.6 nM to 35% (Po0.0001). In MDA-MB-435 cells, Plk1 protein expression was reduced significantly to 18% with 0.056 nM siRNA4 (Po0.0001; Figure 2c ), 0.56 nM to 31% (Po0.05) and 5.6 nM to 2% (Po0.0001). In BT-474 cells, 0.056 nM siRNA4 reduced Plk1 protein expression significantly to 7%, 0.56 nM to 3% and 5.6 nM to 2% (Figure 2d , Po0.0001 for all concentrations). The same concentrations of siRNA4S did not alter Plk1 protein expression in all cell lines tested.
Reduction of Plk1 protein measured by Western blot analysis could be confirmed using indirect immunofluorescence: 0.056 nM siRNA4 reduced Plk1 protein clearly in MCF-7 (Figure 3a) , SK-BR-3 (Figure 3b ), MDA-MB-435 ( Figure 3c ) and BT-474 cells ( Figure 3d ) compared with cells treated with 0.056 nM siRNA4S. In all cell lines, 2-(4-amidinophenyl)-6-indolecarbamidine dihydrochloride (DAPI) staining revealed an elevated number of apoptotic nuclei after siRNA4 treatment.
In our earlier siRNA studies, we were able to show that primary HMECs were not easily transfectable, hence we had to use up to 2 mM to achieve similar transfection efficiencies compared with MCF-7 cells, but using this concentration we were able to reduce Plk1 mRNA and Plk1 protein expression significantly with siRNA4 targeted against Plk1 (Spankuch-Schmitt et al., 2002a) .
Reduction of HER2 expression after treatment with Herceptin and synergistic activation of p27 kip1 in breast cancer cell lines An expanded understanding of the biology of breast cancer has led to the identification of the HER2 receptor as an important parameter associated with an aggressive biological behavior and poor clinical outcome (Nahta and Esteva, 2006b ). To determine the receptor status of the four breast cancer cell lines and of HMECs, we performed a Western blot analysis against HER2 and b-actin. As previously demonstrated (Chen et al., 2000) , BT-474 and SK-BR-3 cells show strong HER2 expression, whereas the level of HER2 was below the limit of detection in MCF-7 and MDA-MB-435 cells (Figure 4a ). HMECs show no HER2 expression compared with the strong HER2-expressing cell line SK-BR-3 (Figure 4b ). Furthermore, we treated BT-474 and SK-BR-3 cells with the humanized monoclonal antibody Herceptin and analysed the cellular content of HER2 protein. Ascending concentrations of Herceptin (0.1-10.0 mg/ml) led to reduced HER2 protein expression 6 days after administration in BT-474 ( Figure 4c ) and SK-BR-3 cells ( Figure 4d ) compared with control cells.
As previously described, p27 kip1 mediates G 0 /G 1 arrest and antiproliferative effects in BT-474 and SK-BR-3 cells induced by Herceptin (Marches and Uhr, 2004) . Here, we raised the question whether the combinatorial treatment with Herceptin and Plk1-specific siRNA enhances the expression of p27 kip1 significantly compared with the application of single agents. In our experiments, treatment with Herceptin alone induced moderate increases in p27 kip1 expression (Figure 4e , Po0.05 for 10.0 mg/ml). After combinatorial treatment with Herceptin and 0.056 nM siRNA4 significant increases of p27 kip1 expression could be observed (Figure 4f , Po0.05 for 0.01, 0.1 and 10.0 mg/ml; Po0.01 for 0.005 mg/ml; and P ¼ 0.1 for 1.0 mg/ml).
Determination of cell proliferation after single treatment Next, we transfected breast cancer cells with Plk1-specific siRNAs, or we treated these cell lines and primary HMECs with anti-neoplastic agents 1 day after subcultivation to monitor their impact on cell proliferation.
siRNA transfection. Whereas in MCF-7 cells, 0.056 nM siRNA4 reduced cell numbers to 39% and 0.56 nM to 44% (P>0.05), 5.6 nM led to a significant reduction of Enhanced drug sensitivity by Plk1-specific siRNA B Spänkuch et al cell numbers to 11% after 96 h compared with control cells (Figure 5a , upper; Po0.05). SK-BR-3 cells showed stronger decreases in cell proliferation than MCF-7 cells after transfection with 0.056-5.6 nM siRNA4 compared with control cells: 0.056 nM reduction to 33% (Po0.05), 0.56 nM to 38% (Po0.05) and 5.6 nM to 9% (Po0.01; Figure 5a , second). In MDA-MB-435 cells, the reduction of cell proliferation correlated to the concentration of siRNA4: 0.056 nM reduced proliferation to 67% (Po0.01), 0.56 nM to 57% (Po0.01) and 5.6 nM to 8% (Po0.0001) compared with control cells (Figure 5a , third). The most pronounced inhibitory effect was observed in BT-474 cells with 1-25% compared with control cells (Figure 5a , lower; Po0.01 for all concentrations after 96 h). For comparison, the transfection of HMECs with ascending doses of siRNA4 (566 nM to 2 mM) did not reduce proliferation compared with untreated control cells, indicating a differential effect between breast cancer cells and primary HMECs (Spankuch-Schmitt et al., 2002a) .
Herceptin. Furthermore, we tested the influence of Herceptin on the proliferation of HER2-positive Enhanced drug sensitivity by Plk1-specific siRNA B Spänkuch et al and -negative cells. Over the period of 24-96 h, we did not observe a reduction in cell proliferation after treatment with Herceptin compared with untreated cells (data not shown). Subsequently, we analysed cell proliferation 2, 6 and 8 days after treatment. In HER2-negative MCF-7 cells, Herceptin did not influence cell proliferation after 2-8 days (Figure 5b, upper) . Eight days after treatment of HER2-positive SK-BR-3 cells, proliferation was reduced significantly for all Herceptin concentrations (Figure 5b , second): 0.01 mg/ ml to 50% (Po0.05), 0.1 mg/ml to 39% (Po0.01), 1.0 mg/ml to 22% (Po0.0001) and 10.0 mg/ml to 15% (Po0.001). In HER2-negative MDA-MB-435 cells, only the highest Herceptin concentration (10.0 mg/ml) reduced cell proliferation to levels of 13% likely due to cytotoxic effects (Figure 5b , third). In BT-474 cells, 0.01 mg/ml Herceptin reduced cell proliferation after 8 days to 72% (P ¼ 0.1), 0.1 mg/ml to 45% (Po0.01), 1.0 mg/ml to 26% (Po0.001) and 10.0 mg/ml to 22% (Po0.001; Figure 5b , fourth). In HER2-negative HMECs, 0.01-10 mg/ml Herceptin did not influence cell proliferation compared with untreated control cells. Still, only the very high dose of 100 mg/ml Herceptin induced cytotoxic cell death in HMECs to levels of 54% compared with untreated control cells (Figure 5b , lower). Determination of cell proliferation after combinatorial treatment Combinatorial drug application as treatment paradigm is very effective in cancer therapy. Thus, we tested the antineoplastic drugs paclitaxel and Herceptin in combination with Plk1-specific siRNAs to identify advantageous combinations that induce strong antiproliferative effects at low drug concentrations. In addition, we analysed the impact of drug combinations on the proliferation of primary cells.
siRNA4 and paclitaxel. First, we analysed the effect of a low siRNA4 concentration (0.056 nM) together with paclitaxel in concentrations from 0.005 to 1.0 mg/ml on the proliferation of MCF-7 cells (Figure 6a , upper). siRNA4 (0.056 nM) alone induced a slight reduction in proliferation to 70% (Po0.01) after 96 h compared with control cells. In combination with 0.005-1.0 mg/ml paclitaxel, proliferation was reduced to 9-4% (Po0.001 for all concentrations). In SK-BR-3 cells, 0.056 nM siRNA4 induced a slight reduction in proliferation to 90% compared with control cells after 96 h (P ¼ 0.05; Figure 6a , second). In combination with 0.005-1.0 mg/ml paclitaxel, proliferation was reduced significantly to 10-3% (Po0.001 for all concentrations). In MDA-MB-435 cells, 0.056 nM siRNA4 induced a significant reduction in proliferation to 60% compared with control cells after 96 h (Po0.01; Figure 6a , third). In combination with 0.005 mg/ml paclitaxel, proliferation was reduced significantly to 67% (Po0.05), with 0.01 mg/ml to 10% (Po0.001), with 0.1 mg/ml to 3% (Po0.0001) and with 1.0 mg/ml to 1% (Po0.0001). In BT-474 cells, 0.056 nM siRNA4 alone induced a significant reduction in proliferation to 22% compared with control cells 96 h after transfection (Po0.05; Figure 6a , fourth). In combination with 0.005-1.0 mg/ ml paclitaxel, proliferation was reduced significantly to 4-0% (Po0.05 for all concentrations). Taken together, although the combination of 0.056 nM siRNA4 with paclitaxel induced synergistic inhibitory effects (combination index (c.i.)o1) on the proliferation of MDA-MB-435 cells, in MCF-7 the combination displayed an additive effect (c.i. ¼ 1). In HMEC, 1 mM siRNA4 alone reduced cell proliferation to 48% (Po0.05), and 1 mM siRNA4 together with 0.005-10.0 mg/ml paclitaxel reduced cell proliferation to 8-0% (Po0.01 for all concentrations; Figure 6 , lower). siRNA4S (1 mM) did not influence cell proliferation compared with control cells. These data indicate that the addition of siRNA4 to HMECs did not enhance the cytotoxic effect of paclitaxel alone. Taken together, in HMECs, the combination of 1 mM siRNA4 with paclitaxel had no stronger influence on the proliferation than paclitaxel alone indicating an antagonistic effect (c.i.>1). Enhanced drug sensitivity by Plk1-specific siRNA B Spänkuch et al slight decrease in cancer cell proliferation compared with control cells after 2, 6 and 8 days, respectively (Figure 6b, upper) . Herceptin (0.01 mg/ml) alone did not reduce cell proliferation after 2 days significantly (P ¼ 0.5). The combination of 0.056 nM siRNA4 with 0.005-1.0 mg/ml Herceptin led to an earlier reduction in cancer cell proliferation compared with single administration of Herceptin; we observed a significant reduction of cell proliferation using 0.01 mg/ml Herceptin together with 0.056 nM siRNA4 after 2 days in SK-BR-3 cells Enhanced drug sensitivity by Plk1-specific siRNA B Spänkuch et al 8 days. Here, we observed a significantly decreased proliferation using 0.005 mg/ml Herceptin together with 0.056 nM siRNA4 already after 2 days to 4% (Po0.001) compared with control cells. In both HER2-positive cell lines, this combination was synergistic after 2 and 6 days (c.i.o1).
Cell cycle distribution of breast cancer cells after treatment with Plk1-specific siRNAs and paclitaxel MCF-7, SK-BR-3, MDA-MB-435, BT-474 cells and HMECs were treated with siRNA and paclitaxel alone and in combinations, and cell cycle distribution was monitored using FACScan analysis. Increasing siRNA4 Enhanced drug sensitivity by Plk1-specific siRNA B Spänkuch et al concentrations induced a more pronounced G 2 /M arrest in all breast cancer cell types compared with control cells: from 9-16% in control cells to 15-42% with 0.056 nM, to 23-34% with 0.56 nM and to 25-59% with 5.6 nM siRNA4 (Figure 7a-d) . The same concentrations of siRNA4S did not alter the G 2 /M content significantly. The percentage of cells in G 2 /M correlated with the extent of apoptosis (Figure 8j -n) confirming a previous observation by Nishii et al. (1996) . Treatment with paclitaxel led to strong G 2 /M arrest in all cancer cell lines: 0.005 mg/ml to 27-49%, 0.01 mg/ml to 39-62%, 0.1 mg/ml to 33-75%, 1.0 mg/ml to 31-75% and 10.0 mg/ml to 21-60%. In all four breast cancer cell lines, the combination of 0.056 nM siRNA4 with 0.005-10.0 mg/ml paclitaxel led to a significant and synergistic G 2 /M arrest to levels of 35-84% (Figure 7a-d ). This G 2 /M arrest is another evidence for apoptotic changes after single or combinatorial treatment with siRNA4 and/or paclitaxel. We pursued this issue by analysing the activation of the caspase pathway with Western blot analyses (Figure 8 ). In HMECs, even the very high dose of siRNA4 (1 mM) did not increase the cell number in G 2 /M phase compared with control cells (Figure 7e ). Increasing concentrations of paclitaxel (0.01-10.0 mg/ml) induced a strong G 2 /M arrest in HMECs; but the combination of 1 mM siRNA4, which alone did not influence cell cycle distribution with increasing concentrations of paclitaxel, led to a weaker G 2 /M arrest than the same concentrations of paclitaxel alone. Hence, in primary cells, the combination of Plk1-specific siRNAs together with paclitaxel did not evoke synergistic effects.
Induction of apoptosis in breast cancer cells after single or combinatorial treatment with paclitaxel, Herceptin and siRNA4
We performed Western blots to determine whether the decreased cell proliferation and the G 2 /M arrest correlate to the induction of apoptosis. Plk1-specific siRNAs alone and paclitaxel alone are able to induce apoptosis, hence we tested whether the combination of both agents leads to a stronger apoptotic reaction than each agent alone. For this reason, we performed Western blots against caspases 9 and 3. In first experiments, we treated MCF-7 cells with increasing concentrations of paclitaxel alone that induced cleavage of caspase 9 (Figure 8a ). After the combinatorial treatment of MCF-7 cells with 0.056 nM siRNA4 and paclitaxel, the cleavage of caspase 9 was comparable (Figure 8b ). Then we treated SK-BR-3 cells with ascending doses of paclitaxel alone (0.01-10.0 mg/ml) and performed anti-caspase 3 and caspase 9 Westernblot analyses. Caspase 3, the executioner caspase in apoptosis, and caspase 9 were clearly activated, as shown by the cleavage of full-length protein (Figure 8c) . Furthermore, we transfected SK-BR-3 cells with siRNA4 and siRNA4S, and observed a dose-dependent caspase 9 cleavage after siRNA4 treatment (Figure 8d ). Because Herceptin alone is known to induce apoptosis only at high concentrations, we analysed the caspases after treatment of HER2-positive SK-BR-3 cells with
Herceptin. Treatment of SK-BR-3 cells with Herceptin alone did not induce strong caspases 3 or 9 cleavage (Figure 8e ), but the combination of 0.056 nM siRNA4 with increasing Herceptin concentrations led to the activation of caspase 3 and 9 compared with control cells (Figure 8f ). In BT-474 cells, treatment with ascending doses of paclitaxel (0.005-10 mg/ml) induced caspase 3 and 9 cleavage (Figure 8g) , which was enhanced after the combinatorial treatment of BT-474 cells with 0.056 nM siRNA4 and paclitaxel (Figure 8h) . In earlier studies, we observed an activation of caspases 3 and 9 in MDA-MB-435 cells after treatment with paclitaxel alone . Combinatorial treatment of MDA-MB-435 cells with Plk1-specific siRNA and paclitaxel led to an enhanced activation of caspases 3 and 9 compared with single treatment with the same siRNA4 concentration (Figure 8i ).
In addition to caspase cleavage, we observed an elevated number of apoptotic nuclei as shown by DAPI staining after combination of 0.056 nM siRNA4 with paclitaxel in MCF-7 (Figure 8j ), SK-BR-3 (Figure 8k ), MDA-MB-435 ( Figure 8l ) and BT-474 cells ( Figure 8m ) compared with single treatment with siRNA4 or paclitaxel alone. In HMECs, we did not observe apoptotic nuclei after transfection with 2 mM siRNA4. After treatment with paclitaxel, we observed an elevated number of apoptotic nuclei, and after the combination of both agents the number of apoptotic nuclei was comparable to single administration of paclitaxel (Figure 8n ).
Discussion
Chemoresistance is one of the main reasons for treatment failures in advanced cancers, where local therapies are insufficient. Only a few types of cancers can be cured with antineoplastic agents, for the most widely distributed types of carcinomas of the adult the effectiveness of chemotherapy is insufficient. In breast cancer, overexpression of HER2 is associated with resistance to chemotherapy and predicts for a poor outcome (Xia et al., 2006) . Hence, new therapies are needed to defeat resistance to antineoplastic agents. One possible approach is the use of nucleic acid-based agents alone or in combination with antineoplastic agents (Spankuch-Schmitt et al., 2002b; Spankuch et al., 2006) . Still, the use of ASOs often correlates with severe toxic side effects according to clinical studies performed during the last two decades (Gleave and Monia, 2005) . Since the discovery of RNAi in mammals (Elbashir et al., 2001) , the preclinical development of siRNAs targeting different cancer-relevant genes has proceeded very rapidly. Many approaches have shown convincing in vitro reduction of target gene expression and inhibition of cancer cell proliferation. A few in vivo studies have successfully been performed to date, for example, silencing of apolipoprotein B by siRNAs in Enhanced drug sensitivity by Plk1-specific siRNA B Spänkuch et al primates (Zimmermann et al., 2006) or siRNAs targeted against macular degeneration in humans (Check, 2005) . One possible target gene for cancer therapy is Plk1, which has multiple functions during the cell cycle. After depletion of Plk1 in cancer cells by siRNA, our studies revealed a strong increase in G 2 /M, an elevated number of apoptotic nuclei, defects in centrosomal maturation and tumor inhibition (Spankuch-Schmitt et al., 2002a) . Various studies emphasized the importance of Plk1 as prime target candidate for drug development in proliferative diseases such as cancer (Eckerdt et al., 2005; Gumireddy et al., 2005; Spankuch and Strebhardt, 2005 ). Thus, we tested the impact of Plk1-specific siRNAs alone or in combination with different antineoplastic agents on the growth of breast cancer cells to search for effective and safe anticancer regimens.
Still, the delivery of the siRNAs is one problem that has to be solved for therapeutical application of siRNAs. To date, it is difficult to deliver synthetic siRNAs in animals or humans to specific organs because pure siRNAs have a half-life time of approximately 15 min in human blood (unpublished data). Recent studies are dealing with the delivery of synthetic siRNAs into animals, even in primates, using cationic liposomes or conjugation to cholesterol (Templeton, 2002; Soutschek et al., 2004; Nogawa et al., 2005; Zimmermann et al., 2006) . In our own approach, the systemic delivery of plasmids for the expression of shRNAs against Plk1 in nude mice was tested (Spankuch et al., 2004) , revealing a significant antitumor effect in vivo. The efficient delivery of RNAi-based drugs will be a challenge for future research.
First, we analysed the effects of Herceptin together with Plk1-specific siRNAs. The mechanism of Herceptin is cytostatic by blocking and downmodulation of the HER2-receptor, by antibody-dependent cellular cytotoxicity as major mechanism of antibody action (Clynes et al., 2000; Therasse, 2002; Dubska et al., 2005; Mimura et al., 2005; Xia et al., 2006; Nahta and Esteva, 2006b) . Herceptin evokes response rates of 15-40% in metastatic HER2-overexpressing breast cancers as single agent (Vogel et al., 2002; Nahta and Esteva, 2006a) . However, the majority of patients with initial response to Herceptin generally acquires resistance within 1 year (Slamon et al., 2001; Nahta and Esteva, 2006b) . Combined with chemotherapeutic drugs like doxorubicin or paclitaxel, it prolongs survival as first-line therapy (Slamon et al., 2001) . Paclitaxel that disrupts microtubule dynamics is known to invoke the mitotic checkpoint. The combination of docetaxel, another member of the taxane family, and Herceptin has been evaluated in clinical phase II studies (Esteva et al., 2002) . The results are encouraging in that the combination of docetaxel and Herceptin demonstrated high levels of activity when used as first-and second-line treatment of HER2-positive metastatic breast cancer cells. Because inhibitors of Plk1 have also been demonstrated to activate the mitotic checkpoint, a cooperative effect with Herceptin could be expected. Our combinatorial studies using siRNAs targeting Plk1 and Herceptin provide the first evidence for synergistic activities in SK-BR-3 and BT-474 cells. Although the treatment of HER2-positive cells with Herceptin alone does not induce apoptosis (Xia et al., 2006) , the combination with Plk1-specific siRNAs showed apoptosis based on cleavage of caspases 3 and 9. In addition, after pre-treatment of SK-BR-3 cells with Plk1-specific siRNAs, we observed an induction of p27 kip1 which mediates the G 0 /G 1 arrest and the antiproliferative effect of Herceptin (Lane et al., 2000; Marches and Uhr, 2004; Dubska et al., 2005) . One experimental approach to overcome Herceptin resistance is the transfection of p27 kip1 which restores Herceptin sensitivity to resistant cell lines (Nahta et al., 2004) . This is in line with our observations in which Plk1-specific siRNAs induced p27 kip1 expression and enhanced the effects of Herceptin in SK-BR-3 cells. Interestingly, silencing of Plk1 seems to sensitize HER2-overexpressing cells to Herceptin, resulting in the induction of apoptosis after treatment with Herceptin.
Because decreased expression of p27 kip1
, which is an inhibitor of cyclin-dependent kinase, is often associated with cancer aggressiveness (Blain et al., 2003) , the significant upregulation of p27 kip1 levels following combinatorial treatment in our studies might suggest a mechanism for improved sensitivity of breast cancer cells. Still, signalling events in breast cancer cells behind this unique interaction between Plk1-specific siRNA at very low concentrations and Herceptin need to be the subject of future investigations.
Next, we tested one family member of the taxanes (paclitaxel (Taxol), docetaxel (Taxotere)), which are used for the treatment of many cancers. They target microtubule dynamics and bind to a subunit of the tubulin heterodimer that form cellular microtubules thereby accelerating the polymerization of tubulin, efficiently stabilizing and inhibiting the depolymerization of the microtubules (Schiff and Horwitz, 1980; Jordan and Wilson, 2004) . Cells show tetraploidy, a transient arrest in mitosis and a multinucleated interphase state, followed by apoptosis (Blajeski et al., 2001) . In our studies, Plk1-specific siRNAs and paclitaxel, two mitotic spindle targeting drugs, exerted synergistic effects together in MDA-MB-435 cells, additive effects in MCF-7 cells and an elevated number of apoptotic nuclei in MCF-7, SK-BR-3, MDA-MB-435 and BT-474 cells. In HMECs, higher concentrations of siRNAs are necessary to achieve similar transfection efficiencies (Spankuch-Schmitt et al., 2002a) , hence we combined a higher dose of Plk1-specific siRNA with paclitaxel, but the observed reduction of proliferation, G 2 /M arrest or the number of apoptotic nuclei was not increased compared with either agent alone.
The traditional approach for the introduction of new agents into cancer therapy has been to add a new drug to accepted or established treatment regimens. Synergistic actions of paclitaxel and Herceptin with siRNAs targeting Plk1 across a wide range of clinical relevant concentrations in HER2-overexpressing breast cancer cells indicate that these are rational combinations to test in preclinical trials. Two additional advantages of these combinations are that they might help reduce the risk of Enhanced drug sensitivity by Plk1-specific siRNA B Spänkuch et al cardio-and neurotoxicity observed with Herceptin and paclitaxel, and that they might reduce general side effects because the concentrations necessary to achieve synergistic actions in breast cancer cells did not affect primary HMECs more than paclitaxel alone.
Materials and methods
siRNAs, antineoplastic agents and antibodies siRNAs were synthesized by Dharmacon Research Inc. (Lafayette, CO, USA) as described (Spankuch-Schmitt et al., 2002a) with following sequences: siRNA4: gau cac ccu ccu uaa aua u and siRNA4S: uca gac acc uca cuu auu a. The antineoplastic agents paclitaxel and Herceptin were from Roche (Mannheim, Germany). Monoclonal anti-human Plk1 (no. SC-17783), anti-caspase 3 (no. SC-7272), rabbit anticaspase 9 (no. SC-8355), rabbit anti-p27 kip1 (no. SC-528), rabbit anti-p38 (no. SC-535) antibodies, goat anti-mouse (no. SC-2031) and goat anti-rabbit (no. SC-2030) secondary antibodies were from Santa Cruz Biotechnology Inc. (Heidelberg, Germany), monoclonal antibody against HER2 (no. OP15L) was from Oncogene Research Products (Calbiochem, Nottingham, UK) and monoclonal antibody against b-actin (no. A-5316) was from Sigma-Aldrich (Taufkirchen, Germany). Antibodies for immunofluorescence studies were rat a-tubulin (no. MCAP77) (Serotec/Biozol, Eching, Germany) and rabbit anti-Plk1 (Yuan et al., 1997) .
Cell culture
Fetal calf serum was purchased from PAA Laboratories (Co¨lbe, Germany). RPMI 1640, phosphate-buffered saline (PBS), Opti-MEM I, oligofectamine, glutamine and trypsin were from Invitrogen (Karlsruhe, Germany), McCoy's 5A from BioWhittaker (Apen, Germany) and Insulin from Calbiochem (Schwalbach, Germany). Minimum essential basal medium (MEBM), trypsin, Trypsin neutralizing solution (TNS), HEPES buffer and Single Quots for the cultivation and subculturing of the HMECs were from Cambrex (Verviers, Belgium). The cell lines MCF-7 and BT-474 were from DSMZ (Braunschweig, Germany), SK-BR-3 cells from ATCC (LGC Promochem, Wesel, Germany) and MDA-MB-435 cells from CLS (Heidelberg, Germany). HMECs were from Cambrex (Verviers, Belgium). All cell types were cultured according to the supplier's instructions.
In vitro transfection with siRNAs and treatment with chemotherapeutic agents Breast cancer cells and primary HMECs were transfected with siRNAs (0.056, 0.56, 5.6, 1 and 2 mM) using the oligofectamine protocol (Invitrogen, Karlsruhe, Germany) as described before (Spankuch-Schmitt et al., 2002a) . For combination studies, paclitaxel or Herceptin, respectively, were added after the 4 h transfection period. Concentrations in single and combinatorial experiments and further analyses were as described .
RNA preparation and RT-PCR analysis of Plk1 and GAPDH expression
Total RNA from cultured cells was isolated using RNeasy mini-kits according to the manufacturer's protocol 24 h after transfection (Qiagen, Hilden, Germany). For reverse transcription-polymerase chain reaction (RT-PCR), the Qiagen OneStep RT-PCR kit was used according to the supplier's instructions (Qiagen, Hilden, Germany). Total RNA 2 mg was added to the PCR-mix containing Plk1-specific or glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-specific primers, respectively. Plk1-specific primers with the following sequences were chosen to generate a DNA fragment of B450 bp in length: aagagatcccggaggtccta and tcattcaggaaaaggttgcc. The RT reaction was carried out at 501C for 30 min, the initial PCR activation step at 951C for 15 min and the amplification loop (951C 30 s, 591C 45 s, 721C 1 min) was repeated 29 times, followed by a final extension step at 721C for 10 min. GAPDHspecific primers with the following sequences were designed to generate a DNA fragment of B210 bp: taaagggcatcctgggcta cact and ttactccttggaggccatgtagg. The RT reaction was carried out at 501C for 30 min, the initial PCR activation step at 951C for 15 min and the amplification loop (951C 30 s, 551C 30 s, 721C 30 s) was repeated 60 times, followed by a final extension step at 721C for 10 min. Resulting DNA fragments were separated on 1% agarose gels and visualized by ethidiumbromide staining.
Plk1 expression levels were routinely normalized to levels of GAPDH expression. The resulting GAPDH-normalized Plk1 levels are presented relative to GAPDH-normalized levels in untreated cells.
Western blot analysis
For Western blot analysis of breast cancer cells, cells were lysed, protein concentration determined and 50 mg of total protein separated as described . HMECs were lysed as described (Spankuch-Schmitt et al., 2002a) . Membranes were incubated for 1 h in 5% non-fat dry milk with monoclonal antibodies against Plk1 (1:100), caspase 3 (1:1000), caspase 9 (1:100), p38 (1:1000), p27 kip1 (1:200) HER2 (1:250), or b-actin (1:200 000) and for 30 min with goat anti-mouse or goat anti-rabbit serum (1:2000) and visualized as described (Spankuch-Schmitt et al., 2002a) .
In Western blot and RT-PCR experiments Plk1, HER2, p27 kip1 , caspases 3 and 9, p38, GAPDH and b-actin expression were quantified with a Kodak gel documentation system (1D 3.5) as described (Spankuch-Schmitt et al., 2002a) .
Analysis of cell structure by indirect immunofluorescence Indirect immunofluorescence was carried out as described (Kauselmann et al., 1999) for subcellular localization of a- Figure 8 Effect of treatment with paclitaxel, Herceptin and siRNA4 on apoptosis of breast cancer cells. Controls were incubated with Opti-MEM I alone. A Western blot analysis against caspase 9 was performed after treatment of MCF-7 cells with paclitaxel (a) and after treatment of MCF-7 cells with siRNA4 and paclitaxel together (b). A Western blot analysis against caspases 3 and 9 was performed 48 h after treatment of SK-BR-3 cells with paclitaxel (c), siRNA4 and siRNA4S (d), 6 days after treatment with Herceptin (e) and 6 days after treatment with siRNA4 combined with Herceptin (f). A Western blot analysis against caspases 3 and 9 was performed after treatment of BT-474 cells with paclitaxel (g) and after treatment with siRNA4 combined with paclitaxel (h). A Western blot analysis against caspases 3 and 9 was performed 48 h after combinatorial treatment of MDA-MB-435 cells with siRNA4 and paclitaxel (i). In all Western blots, b-actin or p38 was stained to confirm equal loading. DAPI staining was performed to detect apoptotic nuclei in MCF-7 (j), SK-BR-3 (k), MDA-MB-435 (l) and BT-474 cells (m) and in HMECs (n) after treatment with siRNA4, paclitaxel or a combination of both agents.
Enhanced drug sensitivity by Plk1-specific siRNA B Spänkuch et al tubulin (to visualize the spindle apparatus; 1:100) and Plk1 (1:100). DNA was stained with DAPI (Sigma-Aldrich, Taufkirchen, Germany). Cells were examined with a fluorescence microscope (Leica, Wetzlar, Germany) using a Â 100 oil-immersion objective.
Fluorescence-activated cell sorting analysis Cell cycle distribution was analysed using a Becton Dickinson FACScan apparatus (Heidelberg, Germany). For the determination of cell cycle distribution, cells were harvested, washed with PBS, fixed and stained as described . For each experiment, 30 000 cells were analysed in triplicate. Percentage of cells in different cell cycle phases was calculated using ModFit LT for Mac.
Statistical methods
Statistical analysis was performed as described (SpankuchSchmitt et al., 2002a) . The combination index was calculated using the following equation: c.i. ¼ (Am) 50 /(As) 50 þ (Bm) 50 / (Bs) 50 , where (Am) 50 is the concentration of drug A necessary to achieve a 50% inhibitory effect (IC 50 ) in the combination, (As) 50 is the concentration of the same drug that will produce the identical level of effect alone, (Bm) 50 is the IC 50 of drug B in the combination and (Bs) 50 is the IC 50 of drug B after single administration. Antagonism is indicated when c.i.>1, c.i. ¼ 1 indicates an additive effect and a c.i.o1 indicates synergy (Chou and Talalay, 1984; Dai et al., 2005) .
